Der blev oftere rapporteret om anormale ASAT - og ALAT- værdier hos Tygacil- behandlede patienter i perioden efter behandling end hos de patienter, som blev behandlet med komparator, hvilket oftere fandt sted under behandling.
AST and ALT abnormalities in Tygacil-treated patients were reported more frequently in the post therapy period than in those in comparator-treated patients, which occurred more often on therapy.